Olsson G, Tuomilehto J, Berglund G, et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY Study. Am J Hypertens 1991;4:151–158.
Kendall MJ. Clinical trial data on the cardioprotective effects of beta-blockade. Basic Res Cardiol 2000;95:125–130.
Cruickshank JM. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J 1980;100:160–178.
Gengo FM, Gabos C. Central nervous system considerations in the use of beta-blockers, angiotensin-converting enzyme inhibitors, and thiazide diuretics in managing essential hypertension. Am Heart J1988;116:305–310.
Dimsdale JE, Newton RP, Joist T. Neuropsychological side effects of beta-blockers. Arch Intern Med 1989;149:514–525.
McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. Pharmacol Ther 1990;46:163–197.
Gleiter CH, Deckert J. Adverse CNS-effects of betaadrenoceptor blockers. Pharmacopsychiatry 1996;29:201–211.
Patel L, Turner P. Central actions of beta-adrenoceptor blocking drugs in man. Med Res Rev 1981;1:387–410.
Westerlund A. Central nervous system side-effects with hydrophilic and lipophilic beta-blockers.EurJ Clin Pharmacol 1985;28:73–76.
Cove-Smith JR, Kirk CA. CNS-related side-effects with metoprolol and atenolol. Eur J Clin Pharmacol 1985;28:69–72.
Kostis JB, Rosen RC. Central nervous system effects of beta-adrenergic-blocking drugs: The role of ancillary properties. Circulation1987;75:204–212.
Drayer DE.Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers. Pharmacotherapy 1987;7:87–91.
Ahmad S. Metoprolol-induced delirium perpetuated by propafenone. Am Fam Physician 1991;44:1142, 1144.
White WB, Riotte K. Propranolol and white rabbits.NEngl J Med 1982;307:558–559.
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.
Parker DL, Hodge JR. Delirium in a coronary care unit. JAMA1967;201:702–703.
Gershon ES, Goldstein RE, Moss AJ, van Kammen DP. Psychosis with ordinary doses of propranolol. Ann Intern Med 1979;90:938–939.
Greenblatt DJ, Koch-Weser J. Adverse reactions to propranolol in hospitalized medical patients: A report from the Boston Collaborative Drug Surveillance Program. Am Heart J 1973;86:478–484.
Gengo FM, Huntoon L, McHugh WB. Lipid-soluble and water-soluble beta-blockers. Comparison of the central nervous system depressant effect. Arch Intern Med 1987;147:39–43.
Gengo FM, Ermer JC, Carey C, Kalonaros GC, McHugh WB. The relationship between serum concentrations and central nervous system actions of metoprolol. J Neurol Neurosurg Psychiatry 1985;48:101–106.
Le Couteur DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998;34:359–373.
Le Couteur DG, Cogger VC, Markus AM, et al. Pseudocapillarization and associated energy limitation in the aged rat liver. Hepatology 2001;33:537–543.
Hickey PL, McLean AJ, Angus PW, Choo EF, Morgan DJ. Increased sensitivity of propranolol clearance to reduced oxygen delivery in the isolated perfused cirrhotic rat liver. Gastroenterology1996;111:1039–1048.
Frohlich ED. Beta-blockers and mental performance. Arch Intern Med 1988;148:777–778.
Stephen SA. Unwanted effects of propranolol.AmJ Cardiol 1966;18:463–472.
Conway J, Greenwood DT, Middlemiss DN. Central nervous actions of beta-adrenoreceptor antagonists. Clin Sci Mol Med 1978;54:119–124.
Fleminger R. Visual hallucinations and illusions with propranolol. Br Med J1978;1:1182.
Fleming PD, Drachman DA. Propranolol, hallucinations, and sleep disturbance. Am J Psychiatry 1982;139:540–541.
Shore JH, Fraunfelder FT, Meyer SM. Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker. J Clin Psychopharmacol1987;7:264–267.
Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. JAMA 1996;275:852–857.
O'Keeffee ST. Delirium in the elderly. Age Ageing 1999;28(Suppl 2):5–8.
Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: Incidence, prevention and management. Drug Saf1999;21:101–122.
Francis J, Martin D, Kapoor WN. A prospective study of delirium in hospitalized elderly. JAMA 1990;263:1097–1101.
Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999;15:15–28.
Trzepacz PT. Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry 2000;5:132–148.
Cruickshank JM, Neil-Dwyer G. Beta-blocker brain concentrations in man. Eur J Clin Pharmacol 1985;28:21–23.
McCaffrey PM,Riddell JG, Shanks RG.Anassessment of the partial agonist activity of Ro 31-1118, flusoxolol and pindolol in man. Br J Clin Pharmacol 1987;24:571–580.
Turner P. Beta-adrenoceptor blockers reduce blood pressure in normal subjects. Br J Clin Pharmacol 1983;15:128.
Brismar K, Mogensen L, Wetterberg L. Depressed melatonin secretion in patients with nightmares due to betaadrenoceptor blocking drugs. ActaMedScand 1987;221:155–158.
Brismar K, Hylander B, Eliasson K, Rossner S,Wetterberg L. Melatonin secretion related to side-effects of betablockers from the central nervous system. Acta Med Scand 1988;223:525–530.